Peptides for Nerve Pain: What the Research Shows
Neuropathic pain — burning, tingling, shooting, or electric sensations from damaged or dysfunctional nerves — is notoriously hard to treat with conventional drugs. A handful of research peptides target the underlying biology: protecting nerves, supporting regeneration, and calming the inflammatory and immune signals that drive neuropathy. This guide ranks them by how much evidence actually exists.
Research context. These are research peptides, not approved treatments for neuropathy. Nerve pain can signal a serious underlying condition (diabetes, compression, autoimmune disease) that needs proper diagnosis. This article is educational only — work with a physician.
Peptides Studied for Nerve Pain
An 11-amino-acid peptide derived from erythropoietin that activates the innate repair receptor without EPO's effect on red blood cells. It is the most directly relevant compound here — studied in human trials for neuropathic pain and small-fiber neuropathy, including in sarcoidosis and diabetes.
Evidence: Human clinical trials for neuropathic pain — the strongest evidence on this list
ARA-290 — Base PeptidesBeyond soft-tissue repair, animal studies describe BPC-157 protecting and regenerating peripheral nerves and improving recovery after nerve injury, including the sciatic nerve. This makes it a common choice in protocols targeting nerve-related pain.
Evidence: Multiple animal nerve-injury models; strong anecdotal human use
BPC-157 — Base PeptidesAn angiotensin IV analog that activates the hepatocyte growth factor (HGF) system, a pathway central to nerve and synapse repair. Research interest centres on its potential to support regeneration in damaged neural tissue.
Evidence: Preclinical; potent in animal models, no human trials
Dihexa — Base PeptidesStudied for increasing BDNF and NGF and protecting neurons against oxidative and ischaemic stress. While most of its data concern central cognition, those same neurotrophic mechanisms are relevant to nerve health and the nervous system's response to pain.
Evidence: Russian clinical use and nootropic research; indirect for nerve pain
Semax — Base PeptidesA tuftsin analog studied for anxiety and neuroinflammation. Chronic nerve pain and the distress that accompanies it are tightly linked, and Selank is researched as a supportive compound addressing that dimension rather than the nerve damage itself.
Evidence: Clinical anxiolytic data; supportive role only
Selank — Base PeptidesMost peptides discussed for nerve pain are extrapolated from repair or cognition research. ARA-290 is different: it was developed specifically to engage the tissue-protective innate repair receptor, and it has been tested in actual human neuropathic-pain trials, including small-fiber neuropathy. That makes it the most evidence-backed option here.
BPC-157 and Dihexa target regeneration of the nerve itself, while Semax and Selank address neuroprotection and the mood/anxiety burden of chronic pain. These roles can be complementary, but combining compounds also makes it harder to attribute any effect.
Neuropathy is a symptom, not a diagnosis. The biggest lever is often managing the underlying driver — blood-sugar control, relieving compression, or treating an autoimmune process. Peptides are studied as an adjunct to that work, not a substitute.
Use suppliers that publish batch-specific third-party certificates of analysis for purity and identity. With neuroactive compounds, quality directly affects both safety and any chance of benefit.
Other Articles
Calculator
Calculate exact reconstitution volumes and insulin unit doses for any peptide protocol.
Open Calculator →